Clinical Trials Logo

Diuretics Drug Reactions clinical trials

View clinical trials related to Diuretics Drug Reactions.

Filter by:
  • None
  • Page 1

NCT ID: NCT05904808 Completed - Clinical trials for Congestive Heart Failure

The Heart Failure Diuresis Efficacy Comparison (DEA-HF) Study

DEA-HF
Start date: April 19, 2023
Phase: Phase 4
Study type: Interventional

To investigate the effectiveness of three (3) IV diuretic regimens to increase natriuresis in volume-overloaded HF patients, allowing for better decongestion and potentially resulting in improved clinical and biochemical parameters outcome.

NCT ID: NCT05411991 Recruiting - Acute Heart Failure Clinical Trials

Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment

DECONGEST
Start date: June 12, 2022
Phase: Phase 4
Study type: Interventional

This is a pragmatic, multicenter, interventional, parallel-arm, randomized, open-label trial to investigate whether a diuretic regimen, based on serial assessment of sodium concentration (UNa) on spot urine samples after diuretic administration and with low-threshold use of combination diuretic therapy, improves decongestion versus usual care in acute heart failure (AHF), potentially leading to better clinical outcomes.

NCT ID: NCT04934228 Recruiting - Obesity Clinical Trials

Mitigating the Pro-inflammatory Phenotype of Obesity

MAPLE
Start date: July 1, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to examine the hypothesize that 4 weeks of sympathetic nerve activity (SNA) inhibition (oral clonidine) will cause a significant reduction in circulating blood concentrations and endothelial cell expression of inflammatory markers (e.g., TNF-α, IL-6). Our study is a prospective study using a randomized, double-blinded design to test 4 weeks of SNA blockade (oral clonidine) compared with a BP-lowering control condition (diuretic, hydrochlorothiazide) or a placebo.

NCT ID: NCT04740242 Completed - Heart Failure Clinical Trials

Metabolic Alkalosis in Heart Failure

Start date: January 1, 2021
Phase:
Study type: Observational

Metabolic alkalosis (MA) is the most common acid-base disorder and when it's severe it can have effects on cellular function and contribute to an increase in mortality. MA is a common complication of heart failure (HF) especially when patients are treated with diuretics, but few studies have analyzed the prevalence of acid-base disorders in patients with HF. All these studies have shown that MA is more common in patients with HF in more advanced stages and that the use of diuretics increases the prevalence of MA. The study hypothesis, based on clinical experience and the few data that exist in the scientific literature, is that MA is a frequent analytical disorder in patients admitted for decompensated HF and that its presence entails a worse short-term vital prognosis. The ALCALOTIC study is an observational cohort and prospective study. The main objectives of the study are the following: 1. To determine the prevalence of MA in patients admitted for decompensated HF 2. To analyze if there are differences in patients admitted for HF according to the presence of MA on admission 3. To determine if the presence of MA has an influence on the short-term prognosis in patients admitted for decompensated HF

NCT ID: NCT04676399 Recruiting - Hypertension Clinical Trials

Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction

PASSION
Start date: February 8, 2022
Phase: Early Phase 1
Study type: Interventional

The purpose of this study (PASSION study) is to monitor symptoms of chronic pain before and after 2 weeks of a standard drug commonly used to treat elevated blood pressure compared with 2 weeks of placebo (crossover design) so that we may better understand how blood pressure affects your level of pain. This study is not testing an experimental drug.